197 related articles for article (PubMed ID: 1461658)
21. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
22. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions.
Pellegata NS; Sessa F; Renault B; Bonato M; Leone BE; Solcia E; Ranzani GN
Cancer Res; 1994 Mar; 54(6):1556-60. PubMed ID: 8137263
[TBL] [Abstract][Full Text] [Related]
23. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas.
Oda H; Nakatsuru Y; Ishikawa T
Cancer Res; 1995 Feb; 55(3):658-62. PubMed ID: 7834636
[TBL] [Abstract][Full Text] [Related]
24. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.
Lehman TA; Bennett WP; Metcalf RA; Welsh JA; Ecker J; Modali RV; Ullrich S; Romano JW; Appella E; Testa JR
Cancer Res; 1991 Aug; 51(15):4090-6. PubMed ID: 1855224
[TBL] [Abstract][Full Text] [Related]
25. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas.
Komuro H; Hayashi Y; Kawamura M; Hayashi K; Kaneko Y; Kamoshita S; Hanada R; Yamamoto K; Hongo T; Yamada M
Cancer Res; 1993 Nov; 53(21):5284-8. PubMed ID: 8221663
[TBL] [Abstract][Full Text] [Related]
26. p53 Mutations in human hepatocellular carcinomas from Germany.
Kress S; Jahn UR; Buchmann A; Bannasch P; Schwarz M
Cancer Res; 1992 Jun; 52(11):3220-3. PubMed ID: 1317262
[TBL] [Abstract][Full Text] [Related]
27. RAS gene mutations in multiple myeloma and related monoclonal gammopathies.
Matozaki S; Nakagawa T; Nakao Y; Fujita T
Kobe J Med Sci; 1991 Feb; 37(1):35-45. PubMed ID: 1921261
[TBL] [Abstract][Full Text] [Related]
28. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China.
Gao H; Wang LD; Zhou Q; Hong JY; Huang TY; Yang CS
Cancer Res; 1994 Aug; 54(16):4342-6. PubMed ID: 8044781
[TBL] [Abstract][Full Text] [Related]
29. Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction.
Stork P; Loda M; Bosari S; Wiley B; Poppenhusen K; Wolfe H
Oncogene; 1991 May; 6(5):857-62. PubMed ID: 1646989
[TBL] [Abstract][Full Text] [Related]
30. Activation of K-ras by codon 13 mutations in C57BL/6 X C3H F1 mouse tumors induced by exposure to 1,3-butadiene.
Goodrow T; Reynolds S; Maronpot R; Anderson M
Cancer Res; 1990 Aug; 50(15):4818-23. PubMed ID: 2196119
[TBL] [Abstract][Full Text] [Related]
31. P53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis.
Chang KW; Sarraj S; Lin SC; Tsai PI; Solt D
Carcinogenesis; 2000 Jul; 21(7):1441-51. PubMed ID: 10874024
[TBL] [Abstract][Full Text] [Related]
32. Absence of p53 gene mutations in primary neuroblastomas.
Vogan K; Bernstein M; Leclerc JM; Brisson L; Brossard J; Brodeur GM; Pelletier J; Gros P
Cancer Res; 1993 Nov; 53(21):5269-73. PubMed ID: 8221661
[TBL] [Abstract][Full Text] [Related]
33. A high frequency of N-RAS oncogene mutations in multiple myeloma.
Tanaka K; Takechi M; Asaoku H; Dohy H; Kamada N
Int J Hematol; 1992 Oct; 56(2):119-27. PubMed ID: 1421173
[TBL] [Abstract][Full Text] [Related]
34. Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism.
Yoshimoto K; Iwahana H; Fukuda A; Sano T; Saito S; Itakura M
Cancer Res; 1992 Sep; 52(18):5061-4. PubMed ID: 1516062
[TBL] [Abstract][Full Text] [Related]
35. FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K-ras mutations.
Marchetti A; Pellegrini S; Bertacca G; Buttitta F; Gaeta P; Carnicelli V; Nardini V; Griseri P; Chella A; Angeletti CA; Bevilacqua G
J Pathol; 1998 Mar; 184(3):240-6. PubMed ID: 9614374
[TBL] [Abstract][Full Text] [Related]
36. Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma.
Sameshima Y; Matsuno Y; Hirohashi S; Shimosato Y; Mizoguchi H; Sugimura T; Terada M; Yokota J
Oncogene; 1992 Mar; 7(3):451-7. PubMed ID: 1312700
[TBL] [Abstract][Full Text] [Related]
37. Sporadic mutations of the p53 gene in multiple myeloma and no evidence for germline mutations in three familial multiple myeloma pedigrees.
Willems PM; Kuypers AW; Meijerink JP; Holdrinet RS; Mensink EJ
Leukemia; 1993 Jul; 7(7):986-91. PubMed ID: 8321049
[TBL] [Abstract][Full Text] [Related]
38. p53 gene mutation in primary human renal cell carcinoma.
Torigoe S; Shuin T; Kubota Y; Horikoshi T; Danenberg K; Danenberg PV
Oncol Res; 1992; 4(11-12):467-72. PubMed ID: 1299377
[TBL] [Abstract][Full Text] [Related]
39. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors.
D'Amico D; Carbone D; Mitsudomi T; Nau M; Fedorko J; Russell E; Johnson B; Buchhagen D; Bodner S; Phelps R
Oncogene; 1992 Feb; 7(2):339-46. PubMed ID: 1312696
[TBL] [Abstract][Full Text] [Related]
40. N-ras and p53 gene mutations are very rare events in multiple myeloma.
Yasuga Y; Hirosawa S; Yamamoto K; Tomiyama J; Nagata K; Aokia N
Int J Hematol; 1995 Aug; 62(2):91-7. PubMed ID: 8590778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
